Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pleural disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    394 result(s) found for: Pleural disease. Displaying page 1 of 20.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-000599-40 Sponsor Protocol Number: Start Date*: 2012-06-13
    Sponsor Name:North Bristol NHS Trust
    Full Title: The efficacy of Indwelling Pleural Catheter placement versus IPC placement PLUS sclerosant (talc) in patients with malignant pleural effusions managed exclusively as out-patients
    Medical condition: Malignant pleural effusions
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035605 Pleural mesothelioma malignant advanced PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10066721 Pleural effusion recurrent LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035606 Pleural mesothelioma malignant localised LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035607 Pleural mesothelioma malignant recurrent PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10035598 Pleural effusion PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035608 Pleural metastases LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061352 Pleural neoplasm PT
    14.1 10042613 - Surgical and medical procedures 10035612 Pleural therapeutic procedures HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035603 Pleural mesothelioma PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10046099 Unspecified pleural effusion LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026673 Malignant pleural effusion PT
    14.1 10042613 - Surgical and medical procedures 10062754 Pleural cavity drainage LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10014313 Effusion pleural LLT
    14.1 10042613 - Surgical and medical procedures 10068942 Implantable pleural catheter insertion PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018275-20 Sponsor Protocol Number: UMCNONCO201001 Start Date*: 2010-03-24
    Sponsor Name:University Medical Centre Nijmegen St Radboud
    Full Title: A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion
    Medical condition: symptomatic malignant ascites or pleural effusion
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025538 Malignant ascites LLT
    12.1 10026673 Malignant pleural effusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000586-26 Sponsor Protocol Number: TIME3UK Start Date*: 2009-03-20
    Sponsor Name:University of Oxford
    Full Title: Adjuvant Urokinase in the Treatment of Malignant Pleural Effusion: The Third Therapeutic Intervention in Maligant Effusion Trial (TIME3-UK). A Randomised Controlled Trial to evaluate whether use of...
    Medical condition: Patients with malignant pleural effusions
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026673 Malignant pleural effusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-009134-32 Sponsor Protocol Number: 2137/09 Start Date*: 2009-04-27
    Sponsor Name:North Bristol NHS Trust
    Full Title: Bristol Randomised Controlled Trial of Zoledronic Acid in Malignant Pleural disease(Pilot Study).
    Medical condition: Malignant pleural disease of all histological cell types. 50% patients in trial will have indwelling pleural catheters for management of breathlessness.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014293-17 Sponsor Protocol Number: AGO/2009/006 Start Date*: 2009-09-10
    Sponsor Name:University Hospital Ghent
    Full Title: Phase II study of cetuximab combined with cisplatin or carboplatin/pemetrexed as first line treatment in patients with malignant pleural mesothelioma.
    Medical condition: Patients with malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10059518 Pleural mesothelioma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002876-10 Sponsor Protocol Number: ONC-2014-002 Start Date*: 2014-10-31
    Sponsor Name:Istituto Clinico Humanitas
    Full Title: A PHASE II STUDY OF THE COMBINATION OF GEMCITABINE AND IMATINIB MESYLATE IN PEMETREXED-PRETREATED PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024496-37 Sponsor Protocol Number: 1716-12 Start Date*: 2012-05-04
    Sponsor Name:Virttu Biologics Limited
    Full Title: A PHASE I/IIa STUDY OF THE SAFETY, TOLERABILITY AND BIOLOGICAL EFFECT OF SINGLE AND REPEAT ADMINISTRATION OF THE SELECTIVELY REPLICATION-COMPETENT HERPES SIMPLEX VIRUS HSV1716 INTO THE TUMOUR-BEAR...
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004433-26 Sponsor Protocol Number: 3638 Start Date*: 2016-05-04
    Sponsor Name:North Bristol NHS Trust
    Full Title: Zoledronic acid in the management of malignant pleural mesothelioma - a feasibility study
    Medical condition: Malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027406 Mesothelioma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035603 Pleural mesothelioma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001016-11 Sponsor Protocol Number: SAKK17/16 Start Date*: 2018-01-31
    Sponsor Name:SAKK
    Full Title: Lurbinectedin Monotherapy in Patients with Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial
    Medical condition: Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002560-28 Sponsor Protocol Number: N19PEM Start Date*: 2020-11-13
    Sponsor Name:NKI-AVL
    Full Title: PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients.
    Medical condition: unresectable malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004429-27 Sponsor Protocol Number: ONC-2006-003 Start Date*: 2007-05-25
    Sponsor Name:ISTITUTO CLINICO HUMANITAS
    Full Title: Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma
    Medical condition: Histologically proven diagnosis of malignant pleural mesothelioma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059518 Pleural mesothelioma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005894-77 Sponsor Protocol Number: 107/2007/O/Sper Start Date*: 2007-12-18
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Phase I/II study with cisplatin and pemetrexed +/- sorafenib in malignant pleural mesothelioma (SoMe study)
    Medical condition: malignant pleural mesothelioma (MPM)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059518 Pleural mesothelioma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000109-10 Sponsor Protocol Number: UNITO-001/2020 Start Date*: 2020-09-30
    Sponsor Name:DIPARTIMENTO DI ONCOLOGIA-UNIVERSITA' DEGLI STUDI DI TORINO
    Full Title: A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive fo...
    Medical condition: patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for PD-L1 expression and germ or somatic mutations in DNA damage repair genes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062042 Lung neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10045155 Tumor of pleura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004475-75 Sponsor Protocol Number: IFCT-1501 Start Date*: 2016-02-08
    Sponsor Name:IFCT
    Full Title: A randomized phase II study evaluating efficacy and safety of 2nd or 3rd line treatment by Nivolumab monotherapy or Nivolumab plus Ipilimumab, for unresectable Malignant Pleural Mesothelioma (MPM) ...
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002180-25 Sponsor Protocol Number: ETOP_13-18 Start Date*: 2019-10-16
    Sponsor Name:European Thoracic Oncology Platform (ETOP)
    Full Title: A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignan...
    Medical condition: advanced malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005201-48 Sponsor Protocol Number: 1199.93 Start Date*: 2013-07-16
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: LUME-Meso: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combina...
    Medical condition: Unresectable Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended) GB (Completed) FR (Completed) DK (Completed) ES (Prematurely Ended) BE (Completed) NL (Prematurely Ended) SE (Completed) PT (Completed) CZ (Completed) AT (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003169-82 Sponsor Protocol Number: rAd-IFN-MM-301 Start Date*: 2019-01-30
    Sponsor Name:Trizell Ltd
    Full Title: A Phase III, Open Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination wit...
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005171-95 Sponsor Protocol Number: MESOT-TREM-2008 Start Date*: 2008-09-15
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMANIZED ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA
    Medical condition: PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059518 Pleural mesothelioma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002721-30 Sponsor Protocol Number: NIPU Start Date*: 2021-01-14
    Sponsor Name:Oslo University Hospital
    Full Title: Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study)
    Medical condition: Malignant pleural mesothelioma (MPM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023614-31 Sponsor Protocol Number: IPR25 Start Date*: 2011-03-09
    Sponsor Name:MOLMED
    Full Title: NGR019: Randomized double-blind phase II study of NGR-hTNF versus placebo as maintenance treatment in advanced malignant pleural mesothelioma (MPM)
    Medical condition: Advanced MPM patients with non-progressive disease after six cycles of a first-line, pemetrexed-based regimen
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035605 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Oct 29 01:19:02 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA